ATE424191T1 - Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung - Google Patents

Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung

Info

Publication number
ATE424191T1
ATE424191T1 AT00904586T AT00904586T ATE424191T1 AT E424191 T1 ATE424191 T1 AT E424191T1 AT 00904586 T AT00904586 T AT 00904586T AT 00904586 T AT00904586 T AT 00904586T AT E424191 T1 ATE424191 T1 AT E424191T1
Authority
AT
Austria
Prior art keywords
weight percent
pharmaceutical formulations
tablet
extended release
release pharmaceutical
Prior art date
Application number
AT00904586T
Other languages
German (de)
English (en)
Inventor
Kevin ENGH
Yihong Qiu
Venkatramana Rao
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE424191T1 publication Critical patent/ATE424191T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00904586T 1999-02-04 2000-01-26 Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung ATE424191T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24467899A 1999-02-04 1999-02-04

Publications (1)

Publication Number Publication Date
ATE424191T1 true ATE424191T1 (de) 2009-03-15

Family

ID=22923698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904586T ATE424191T1 (de) 1999-02-04 2000-01-26 Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung

Country Status (10)

Country Link
EP (1) EP1146864B1 (enExample)
JP (2) JP5420126B2 (enExample)
AT (1) ATE424191T1 (enExample)
CA (1) CA2361496C (enExample)
CY (1) CY1108863T1 (enExample)
DE (1) DE60041691D1 (enExample)
DK (1) DK1146864T3 (enExample)
ES (1) ES2321908T3 (enExample)
PT (1) PT1146864E (enExample)
WO (1) WO2000045793A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020025341A1 (en) * 1998-12-18 2002-02-28 Yihong Qiu Controlled release formulation of divalproex sodium
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2002051402A1 (en) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2004071421A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Sustained release formulation of n-(2-propylpentanoyl) glycinamide and related compounds
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
CN107811985B (zh) * 2016-09-13 2021-05-28 四川科瑞德制药股份有限公司 一种抗癫痫缓释制剂及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
AU6824996A (en) * 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
CA2254078A1 (en) * 1997-03-11 1998-09-17 Hexal Ag Solid, non-deliquescent formulations of sodium valproate

Also Published As

Publication number Publication date
EP1146864A1 (en) 2001-10-24
JP5420590B2 (ja) 2014-02-19
CY1108863T1 (el) 2014-07-02
JP5420126B2 (ja) 2014-02-19
WO2000045793A1 (en) 2000-08-10
CA2361496C (en) 2011-06-07
JP2011241218A (ja) 2011-12-01
DK1146864T3 (da) 2009-05-11
JP2002536318A (ja) 2002-10-29
CA2361496A1 (en) 2000-08-10
EP1146864B1 (en) 2009-03-04
PT1146864E (pt) 2009-03-20
ES2321908T3 (es) 2009-06-15
DE60041691D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
ES2376199T3 (es) Un comprimido farmacéutico caracterizado por mostrar un incremento de volumen cuando entra en contacto con fluidos biológicos.
ES2205243T3 (es) Forma medicamentosa estable con derivados de dencimidazol como sustancia activa, destinada a su administracion por via oral, y procedimientopara su preparacion.
KR20030013460A (ko) 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형
HUP9800516A2 (hu) Gyógyszerforma kevéssé oldódó, bázisos gyógyszerhatóanyagok szabályzott felszabadítására
EA200200595A1 (ru) Лекарственная форма с высвобождением лекарства под действием гидрогеля
EP0136103B1 (en) Amosulalol hydrochloride long acting formulations
DE69331906D1 (de) Granulierte pharmazeutische zusammensetzung
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
CA2352211A1 (en) Sustained release matrix systems for highly soluble drugs
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
Halsas et al. Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
JP3247693B2 (ja) 徐放性製剤
BR0212155A (pt) Composição farmacêutica
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
ES2186207T3 (es) Metodo para preparacion de formulaciones farmaceuticas.
IT1303753B1 (it) Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
KR20130121717A (ko) 위체류 약물전달 시스템을 이용한 서방성 제제
JP2930374B2 (ja) 口腔内貼着型膜製剤
Gupta et al. Ion exchange resins transforming drug delivery systems
EP0121901A1 (en) pH independent controlled releasable tablets
Omidian et al. Oral targeted drug delivery systems: gastric retention devices
Palle Formulation and Evaluation of Extended Release Hydrogel of an Antiretroviral Drug

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1146864

Country of ref document: EP